MRSA testing market seen reaching $5.28 billion by 2030

The global market for methicillin-resistant Staphylococcus aureus testing is projected to grow from $3.95 billion in 2025 to $5.28 billion by 2030, driven by hospital infection control needs and faster diagnostic tools. North America leads today, while Asia-Pacific is expected to grow the fastest over the forecast period.

Why it matters: - MRSA testing helps hospitals and labs detect antibiotic-resistant bacteria faster, contain infections and guide treatment. - Rising hospital-acquired infections are keeping demand for reliable diagnostics high. - The market outlook points to continued spending on infection surveillance, molecular testing and automated lab systems.

What happened: - The Business Research Company projected the MRSA testing market will rise from $3.95 billion in 2025 to $4.18 billion in 2026. - The report forecasts the market will reach $5.28 billion by 2030. - The forecast implies a 6.0% compound annual growth rate from 2026 to 2030. - The company released its Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Global Market Report 2026. - The report covers market size, trends and forecasts for 2026-2035. - A free sample of the market report is available. - The full market report is also available.

The details: - Historical growth was supported by rising hospital-acquired infections, higher awareness of antibiotic resistance, expanded diagnostic laboratory infrastructure, stronger hospital infection control programs and more use of culture-based diagnostic methods. - The report says growth through 2030 will be driven by greater adoption of rapid molecular diagnostics, more investment in precision medicine and pathogen genomics, wider use of automated laboratory systems, demand for real-time infection surveillance and tighter regulation to control antimicrobial resistance. - Key trends include more point-of-care MRSA testing in hospitals, broader automated microbiology workflows, expanded infection surveillance programs and higher demand for multiplex assays for hospital-acquired infection screening. - MRSA testing includes molecular diagnostics, culture-based techniques and immunoassays used to detect MRSA in clinical samples. - The testing is used in hospitals, diagnostic laboratories and outpatient settings. - The goal is to prevent spread of infection and support antibiotic selection. - In August 2025, the UK Health Security Agency reported 81 MRSA bacteremia cases, up 8.0% from 75 cases in August 2024. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest during the forecast period. - Other regions in the analysis include South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa.

Between the lines: - The market forecast suggests healthcare systems are prioritizing faster answers over traditional testing alone. - Growth in rapid molecular testing and automation points to pressure on labs to improve turnaround time and throughput. - The regional outlook reflects mature demand in North America and faster infrastructure buildout in Asia-Pacific. - The report’s added features, including market attractiveness scoring, TAM analysis, company scoring matrices and forecasting dashboards, signal a more data-heavy sales pitch to buyers and investors.

What's next: - Hospitals and labs are likely to keep expanding MRSA screening as infection control remains a priority. - Demand should continue shifting toward point-of-care tools, automated workflows and multiplex assays. - The market will likely stay tied to broader antimicrobial resistance policy and surveillance efforts.

The bottom line: - MRSA testing is moving from a niche diagnostic category to a steady-growth market shaped by infection control, faster testing and rising resistance pressures.